Table 2.

Patients Were Grouped into 4 Different Subgroups According to Expected Immune Impairment Attributable to Their Immunosuppressive Treatment

	HM (n = 100)	ST (n = 114)	ID (n = 79)	ND (n = 82)
No therapy	20 (20.0%)	5 (4.6%)	0 (0%)	4 (4.9%)
Low riska	30 (30.0%)	57 (52.3%)	1 (1.3%)	24 (29.3%)
Medium riskb	15 (15.0%)	47 (43.1%)	37 (46.8%)	21 (25.6%)
High riskc	35 (35.0%)	0 (0%)	41 (51.9%)	33 (40.2%)

Abbreviations: HM, hematological malignancies; ID, immunorheumatological diseases; ND, neurological disorders; ST, solid tumors.

Low risk: anti-CD30 MoAb, checkpoint inhibitors MoAb; target therapies; hypomethylation agents, or corticosteroids.

Medium risk: chemotherapy (ongoing or in the last 6 months); Bruton’s tyrosine kinase inhibitors; BCL-2 inhibitors; anti-CD38 MoAb without immunomodulatory drugs (IMIDs); immunosuppressive agents like methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine.

High risk: Anti-B-cell therapy (ongoing or in the last 12 months): anti-CD20 monoclonal antibody (MoAb) or anti-CD19 chimeric antigen receptor T-cell therapies); allogeneic HSCT.